Can a new drug Namilumab help people with pulmonary sarcoidosis?

Upcoming study
Expected to open
This study is currently recruiting
Expected to close January 2025
This study is closed
This study closed in January 2025
We will update this page with study results when available.
Information on study results are included below
This study closed in January 2025
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

Treatments remain limited for people with pulmonary sarcoidosis. Initial treatment often involves taking corticosteroids which can help to reduce inflammation in the body. Some people are also prescribed immunosuppressant drugs. These treatments are not always effective and can lead to unwanted side effects.

The RESOLVE-Lung study is looking at a new drug, called namilumab. This drug is a human monoclonal antibody (mAB) that researchers think could help to treat the underlying cause of the disease. The study aims to find out how the body responds to the drug and if it is effective for helping people with pulmonary sarcoidosis.


What is involved?

You will be assigned to one of two groups.

  • Group 1 will receive the study drug, namilumab, through an injection. The injections are every month for six months.
  • Group 2 will receive a placebo injection. This is something that looks exactly like the drug, but there are no active drug ingredients in the injections.

You will not know which group you have been assigned to until the end of the study. After the study has finished, regardless of which group you were in, you may be given the option to take namilumab for an additional six months, if you would like to.

The researchers will measure your lung function at different points in the study, take blood tests and ask you to complete questionnaires to see if there are any benefits for taking the drug and potential side effects.

Summary of involvement

Monthly injections for 6 months

Lung function tests

Other medical assessments


Can I take part?

You may be able to take part if you are over the age of 18 years and have a diagnosis of pulmonary sarcoidosis.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Diagnosis of pulmonary sarcoidosis at least 6 months ago

Aged 18 years and over

Body Mass Index (BMI) of less than 40 kg/m2

Vaccinated against COVID-19 at least 2 weeks before the start of the study

If taking corticosteroid medication, such as prednisone, you must be on a stable dose of 25 mg/day or less. Or willing to reduce the dose when taking part in the study

You will not be able to join the study of any of the following applies:

You cannot take part if you have been in hospital due to respiratory illness 30 days before the study starts

Women who are pregnant or breastfeeding

Extremely low or high blood pressure

Receiving immunosuppressant therapy, such as methotrexate. However, you may be able to take part if willing to stop this during the study

What difference could taking part make?

Taking part in this study will help researchers to understand if the new drug, namilumab, has the potential to help people with pulmonary sarcoidosis.

Where does the study take place?

Study locations




You may be able to take part in the study if you do not live close to the study locations, but are willing and able to travel to the sites. Travel and other expenses may be covered by the sponsors of the study, but this must be discussed with the research team.

How to take part

If you would like to find out more about taking part or what research opportunities are available for you, we would encourage you to ask your healthcare team.

You can also find out more about the study on the Sarcoidosis Trial website, where you can also answer a set to questions to see if you may qualify taking part in the study.

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Kinevant Sciences GmbH
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email